home / stock / adilw / adilw news

ADILW News and Press, Adial Pharmaceuticals Inc Warrant From 10/22/20

Stock Information
Company Name: Adial Pharmaceuticals Inc Warrant
Stock Symbol: ADILW
Market: NASDAQ
Website: adialpharma.com
Menu
ADILW ADILW Quote ADILW Short ADILW News ADILW Articles ADILW Message Board
Get ADILW Alerts

News, Short Squeeze, Breakout and More Instantly...
ADILW - Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices

FREEHOLD, N.J. and CHARLOTTESVILLE, Va., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO ) (“A valon ”) , a clinical-stage, global developer of cell-based technologies and therapeutics and Adial Pharmaceuticals, Inc. (NASDAQ...
ADILW - Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / October 21, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has reactivated Adial's...

ADILW - Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices

CHARLOTTESVILLE, VA / ACCESSWIRE / September 30, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received an initial firm order for the purchase o...

ADILW - Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples

CHARLOTTESVILLE, VA / ACCESSWIRE / September 29, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has issued an emergen...
ADILW - Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA

CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has submitted a formal request to the U.S. Food and Drug Admin...

ADILW - Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

CHARLOTTESVILLE, VA / ACCESSWIRE / September 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the H.C. Wainwright Annual Global In...

ADILW - Adial Pharmaceuticals to Present at The LD Micro 500 Virtual Conference on September 2nd

CHARLOTTESVILLE, VA / ACCESSWIRE / September 1, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the LD Micro 500 Virtual Investo...
ADILW - Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has entered into an agreement with Brik LLC ("Brik"), an ...

ADILW - Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call

Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and Joseph A. M. Truluck, Chief Financial Officer CHARLOTTESVILLE, VA / ACCESSWIRE / July 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ...

ADILW - Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder

EMA Agreement paves the way for a marketing authorization in Europe after Phase 3 CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addict...
Previous 10 Next 10